Drug Trial Radar · NCT07217119
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM
Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25
Actual
Start
Nov 26, 2019
Primary completion
Apr 17, 2025
Study completion Mar 11, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).
Conditions
- Multiple Myeloma
Interventions
Belantamab mafodotinDrug
Belantamab mafodotin will be administered.
FeladilimabDrug
Feladilimab will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
- DE Phase: Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 281 weeks
- DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to approximately 281 weeks.
- DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to approximately 281 weeks.
- Cohort Expansion (CE) Phase: Overall Response Rate (ORR)Time frame: Up to approximately 281 weeks.
Locations
11 sites in 8 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Madison, Wisconsin
GSK Investigational Site
Fitzroy, Victoria, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Utrecht, Netherlands
GSK Investigational Site
Pamplona Navarra, Spain
GSK Investigational Site
Stockholm, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.